Home » Newsletters » BioWorld Science

BioWorld Science

April 9, 1998

View Archived Issues

CombiChem and Icos announce drug discovery collaboration

Mitotix describes novel inhibitors of the CDK/cyclin complexes

NPY Y1 receptor ligands for eating and cardiovascular disorders

New COX-2-selective compounds in development at Merck Frosst

Novel GH secretagogues disclosed by Novo Nordisk

MS&D describes novel class of antimigraine agents

EGFR tyrosine kinase inhibitor from Novartis will proceed to clinical testing

Chemistry of new immunosuppressive triterpenoid elucidated by Merck & Co.

Flk-1/KDR receptor tyrosine kinase inhibitor SU-5416 characterized at ACS meeting

New agents for BPH emerge from Synaptic/Merck & Co. collaboration

VIMRx and Columbia U. form new drug discovery and development company

Interneuron receives fast track designation for CerAxon

TNFR:Fc evaluated clinically for congestive heart failure

Cytovia raises USD 10 million for development and commercialization of proprietary technology

Pharmacokinetic/safety results reported from ongoing phase I trial of Spartaject busulfan

Cyclic depsipeptide from Streptomyces induces apoptosis in tumor cells

Klinge identifies new apoptosis inducers active against MDR cell lines

Chinese scientists discover novel antitumor antibiotic

Hokuriku Seiyaku seeks development partners for novel antihistamine

New cell therapy developed at Wistar Institute shows potential as chemotherapy adjuvant

PKCbeta inhibitor from Lilly may potentiate effects of radio- and chemotherapy

Mechanism of cytotoxic effect of ImmTher

Aplidine evaluated for activity in animal models of lymphoma, prostate and gastric cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...